Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/6136
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcManus, P.en
dc.contributor.authorMarley, J.en
dc.contributor.authorBirkett, D.en
dc.contributor.authorLinder, J.en
dc.date.issued1998en
dc.identifier.citationBritish Journal of Clinical Pharmacology, 1998; 46(4):409-411en
dc.identifier.issn0306-5251en
dc.identifier.issn1365-2125en
dc.identifier.urihttp://hdl.handle.net/2440/6136-
dc.description.abstract<h4>Aims</h4>To determine among a cohort of patients newly dispensed a prescription for a proton pump inhibitor (PPI) the extent of prior use of other less expensive agents such as antacids and H2-receptor antagonists as evidence of a 'stepped care' approach to peptic ulcer and oesophageal disease.<h4>Methods</h4>A retrospective drug utilization study was conducted within the Pharmaceutical Benefits Scheme (PBS) claims database in Australia. A cohort of social security recipients, who received approval for PPI supply in the month of October 1996, had no prior PPI approval in the previous 18 months and went on to have the drug dispensed, was assembled. This group of 'new PPI starters' was then examined for supply of less expensive prescription medicines to treat peptic ulcer and oesophageal disease in the 12 months prior to obtaining their PPI approval.<h4>Results</h4>In a cohort of 4554 defined new PPI users, 1205 (26.5%) showed no use of H2-receptor antagonists, antacids, cisapride, cytoprotectants or antiregurgitants in the 12 month period prior to commencing the PPI. The major reason for use given by prescribers for PBS supply was 'severe refractory ulcerating oesophagitis'.<h4>Conclusions</h4>Subsidized supply is currently restricted on cost-effectiveness grounds to refractory peptic ulcer disease or severe oesophageal disease. Despite this, utilization and epidemiological data suggest that there is widespread leakage of use outside these indications particularly to less severe forms of oesophageal disease. This patient tracking study has shown within the PBS database that around a quarter of the patients are treated directly with a PPI without being prescribed less expensive agents at least in the preceding 12 months.en
dc.description.statementofresponsibilityMcManus, Peter; Marley, John; Birkett, Donald J.; Lindner, Julieen
dc.language.isoenen
dc.publisherBLACKWELL SCIENCE LTDen
dc.subjectHumans; Esophageal Diseases; Peptic Ulcer; Proton Pumps; Anti-Ulcer Agents; Retrospective Studies; Cohort Studies; National Health Programs; Drug Utilization; Guideline Adherence; Australia; Proton Pump Inhibitors; Drug Prescriptionsen
dc.titleCompliance with restrictions on the subsidized use of proton pump inhibitors in Australiaen
dc.typeJournal articleen
dc.identifier.doi10.1046/j.1365-2125.1998.00791.xen
pubs.publication-statusPublisheden
Appears in Collections:General Practice publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.